Pharma
Piramal Pharma Ltd
PPLPHARMA · NSE · INE0DK501011Market Cap—
P/E—
P/B—
EPS—
Div Yield—
ROE-4.0%
ROCE-1.4%
ROE-4.0%
1Y Return+34.33%
Avg. Volume5.5M
Price Chart
About
Piramal Pharma Ltd is a Pharma company listed on NSE.
Technicals
Free account
Register freeTechnicals
Create a free account to view momentum, moving averages, and delivery signals.
Quant
Premium
UpgradeQuant metrics
Upgrade to view volatility, drawdown, factor, and risk metrics.
Key Ratios
Market Cap—
Current Price—
52W High / Low—
Stock P/E—
Price to Book—
EPS (TTM)—
Dividend Yield—
ROE-4.0%
1Y Return+34.33%
Day Change—
Profit & Loss
| Period | TTM | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|---|---|
| Sales | ₹9,205 Cr | ₹8,869 Cr | ₹9,151 Cr | ||||
| Expenses | ₹8,195 Cr | ₹7,947 Cr | ₹7,706 Cr | ||||
| Operating Profit | ₹1,010 Cr | ₹922 Cr | ₹1,445 Cr | ||||
| OPM % | 11.0% | 10.0% | 16.0% | ||||
| Other Income | ₹86 Cr | ₹74 Cr | ₹208 Cr | ||||
| Depreciation | ₹858 Cr | ₹831 Cr | ₹816 Cr | ||||
| Interest | ₹343 Cr | ₹341 Cr | ₹422 Cr | ||||
| Profit Before Tax | ₹-104 Cr | ₹-176 Cr | ₹415 Cr | ||||
| Tax | ₹210 Cr | ₹150 Cr | ₹324 Cr | ||||
| Net Profit | ₹-314 Cr | ₹-326 Cr | ₹91 Cr | ||||
| EPS (₹) | -2.4 | -2.5 | 0.7 | ||||
| Dividend Payout % | — | 0% | 20% |
Financial history locked
Register freeRegister free to see 4 more years.
Quarterly Results
| Quarter | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹2,270 Cr | ₹2,752 Cr | ₹2,140 Cr | ₹2,044 Cr | |||||||||
| Expenses | ₹2,075 Cr | ₹2,291 Cr | ₹1,944 Cr | ₹1,885 Cr | |||||||||
| Operating Profit | ₹195 Cr | ₹461 Cr | ₹196 Cr | ₹159 Cr | |||||||||
| OPM % | 9.0% | 17.0% | 9.0% | 8.0% | |||||||||
| Depreciation | ₹224 Cr | ₹218 Cr | ₹213 Cr | ₹203 Cr | |||||||||
| Interest | ₹88 Cr | ₹83 Cr | ₹89 Cr | ₹82 Cr | |||||||||
| Net Profit | ₹-69 Cr | ₹-9 Cr | ₹-136 Cr | ₹-99 Cr | |||||||||
| EPS (₹) | -0.5 | -0.1 | -1.0 | -0.8 |
Quarterly history locked
Register freeRegister free to see 9 more quarters.
Balance Sheet
| Period | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹1,327 Cr | ₹1,324 Cr | ₹1,323 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹6,835 Cr | ₹6,801 Cr | ₹6,588 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Borrowings | ₹5,675 Cr | ₹4,856 Cr | ₹4,710 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities | ₹3,770 Cr | ₹2,448 Cr | ₹2,462 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ₹17,607 Cr | ₹15,429 Cr | ₹15,083 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed Assets | ₹8,684 Cr | ₹8,133 Cr | ₹7,990 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments | ₹437 Cr | ₹291 Cr | ₹385 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Equivalents | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Assets | ₹7,386 Cr | ₹6,028 Cr | ₹5,592 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Assets | ₹17,607 Cr | ₹15,429 Cr | ₹15,083 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance sheet history locked
Register freeRegister free to see 4 more years.
Cash Flow
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| FY26 | ₹1,653 Cr | ₹-820 Cr | ₹-39 Cr | ₹794 Cr |
| FY25 | ₹892 Cr | ₹-488 Cr | ₹-441 Cr | ₹-37 Cr |
| FY24 | ₹1,005 Cr | ₹-416 Cr | ₹-422 Cr | ₹166 Cr |
| FY23 | ||||
| FY22 | ||||
| FY21 |
Cash flow history locked
Register freeRegister free to see 4 more years.
Peer Comparison
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | — | — | +14.78% | +7.18% |
| Dr Reddys Laboratories Ltd | — | — | +8.84% | -3.74% |
| Cipla Ltd | — | — | +11.77% | -5.50% |
| Apollo Hospitals Enterprise Ltd | — | — | +22.64% | +23.01% |
| Divis Laboratories Ltd | ₹2,50,065 Cr | 83.9 | +16.5% | +46.29% |
Mutual Fund Holdings
Free account
Register freeMutual fund holdings
Create a free account to see institutional ownership snapshots.
Bulk & Block Deals
Free account
Register freeBulk & block deals
Create a free account to view recent institutional deal activity.
Analyst Estimates
Free account
Register freeAnalyst estimates
Create a free account to view analyst estimate summaries.
Latest News
2026-09-08Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationBSE Filing2026-08-18Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private LimitedCNW Group2026-08-04Piramal Pharma Solutions Expands Peptide API Facility with Advanced Spray Drying SuiteCNW Group2026-08-04Piramal Pharma Ltd (BOM:543635) (Q1 2027) Earnings Call Highlights: Strong Revenue Growth and ...GuruFocus.com2026-06-22Piramal Pharma Solutions Highlights Strong Performance Across More Than 200 Customer AuditsCNW Group
Documents & Filings
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.